Progression of salivary gland dysfunction in patients with Sjögren’s syndrome

Background: Salivary gland dysfunction is one of the key manifestations of Sjögren’s syndrome. Objectives: (1) To assess prospectively loss of function of individual salivary glands in patients with primary and secondary Sjögren’s syndrome in relation to disease duration and use of immunomodulatory...

Full description

Saved in:
Bibliographic Details
Published in:Annals of the rheumatic diseases 2007-01, Vol.66 (1), p.107-112
Main Authors: Pijpe, J, Kalk, W W I, Bootsma, H, Spijkervet, F K L, Kallenberg, C G M, Vissink, A
Format: Article
Language:English
Subjects:
Adult
Aged
Biological and medical sciences
Case-Control Studies
Chlorides - analysis
Disease Progression
disease-modifying antirheumatic drug
DMARD
Exocrine glands
Extended Report
Female
Follow-Up Studies
Humans
IgM-Rf
Immunoglobulins
Male
Medical sciences
Middle Aged
Multivariate Analysis
Parotid Gland - immunology
Parotid Gland - secretion
primary Sjögren’s syndrome
Proteins
pSS
rheumatoid factor
Saliva - chemistry
Salivary Glands - immunology
Salivary Glands - secretion
Salivation
Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis
secondary Sjögren’s syndrome
Secretory Rate
Sjogren's Syndrome - immunology
Sjogren's Syndrome - physiopathology
SM/SL
Sodium - analysis
sSS
Sublingual Gland - immunology
Sublingual Gland - secretion
Submandibular Gland - immunology
Submandibular Gland - secretion
submandibular/sublingual
Time Factors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Salivary gland dysfunction is one of the key manifestations of Sjögren’s syndrome. Objectives: (1) To assess prospectively loss of function of individual salivary glands in patients with primary and secondary Sjögren’s syndrome in relation to disease duration and use of immunomodulatory drugs. (2) To study changes in sialochemical and laboratory values and subjective complaints over time. Methods: 60 patients with Sjögren’s syndrome were included in this study. Whole and gland-specific saliva (parotid and submandibular/sublingual (SM/SL)), samples were collected at baseline and after a mean of 3.6 (SD 2.3) years of follow-up. Disease duration was recorded for all patients. Results: Patients with Sjögren’s syndrome with short disease duration had significantly higher stimulated flow rates at baseline than those with longer disease duration (p
ISSN:0003-4967
1468-2060
DOI:10.1136/ard.2006.052647